Hypercoagulable States and New Anticoagulants, An Issue of Hematology/Oncology Clinics of North America, 1st Edition

Authors :
Mark Crowther & Marco Donadini
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for ...view more
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.
Add to Cart
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.

Author Information
By Mark Crowther, MD, MSc, FRCPC and Marco Donadini, MD